Keywords: Synexus, Cognitive impairment, Alzheimer's disease, Clinical trials

Synexus focuses on mild cognitive impairment studies

Article | 16 November 2010

Mild cognitive impairment (MCI) is under the pharmaceutical spotlight as the number of clinical trials currently underway has increased significantly ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in